Citadel Advisors
AARD

Citadel Advisors’s Aardvark Therapeutics AARD Stock Holding History

Citadel Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$199K Buy
+52,900
New +$548K ﹤0.01% 11423

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's AARD Position: Q1 2026 in Review

Citadel Advisors reduced its Aardvark Therapeutics (AARD) stake by 3.6% in Q1 2026, selling an estimated $482K and leaving 1,242,777 shares worth $4.69M. The position accounts for ﹤0.01% of the portfolio, ranked #4452.

Citadel Advisors first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $18.1M in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Citadel Advisors held 1,242,777 shares of Aardvark Therapeutics worth $4.69M as of Q1 2026.
  • Citadel Advisors sold 46,486 Aardvark Therapeutics shares in Q1 2026, an estimated $482K.
  • Aardvark Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4452 holding.
  • Citadel Advisors first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Citadel Advisors's Aardvark Therapeutics position peaked at $18.1M in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.